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It was initially an error that led me to develop non-invasive bio-
markers of liver diseases [1]. After perforating the gallbladder of a
friend in 1990, I wished that one day the assessment of patients
with chronic liver disease could be carried out rapidly with non-
invasive techniques and without the use of a liver biopsy. My ﬁrst
biomarker had no industrial development [2] but the others
thereafter had professional developments, such as FibroTest with
500,000 tests prescribed worldwide in the last 7 years [3].
Twenty years later, it seems that there is little controversy con-
cerning the utility of the most validated biomarkers versus biopsy
[4–6]. Over the last 7 years, the opinions of more than 50 leaders
from Nid Afdhal [7] to Vlad Ratziu [8] have been published on
these biomarkers. From the evidence-based data, I will summarize
my understanding of the main points of agreement and disagree-
ment in 2010 and the main priorities for the years ahead.Points of agreement
The three major consensual facts recognized by leaders and spe-
cialized clinicians are: (1) 20% of the world population can be
reassured about their liver ﬁbrosis progression rate; (2) biopsy,
even 25 mm in length, is not a gold standard and has a 35%
false-positive and false-negative rate for ﬁbrosis stage/classiﬁca-
tion versus large surgical biopsies; and (3) FibroTest and Fibro-
Scan are the most validated biomarkers for advanced ﬁbrosis,
with accuracies of around 80% when liver biopsy is taken as a ref-
erence and standardized according to stage spectrum.Points of disagreement
Disagreements between leaders clearly appear when they pro-
pose diagnostic strategies. These variations in guidelines can be
summarized using virtually three caricatured proﬁles. The world
being small, any resemblance to living leaders is not intentional.Journal of Hepatology 20
E-mail address: tpoynard@teaser.frMoreover, the opinions of leaders are not so different if adjusted
for the target population and if appropriate statistical methods
are understood and shared.
(1) The ‘‘Biopsist’’ still recommends biopsy as the ﬁrst-line esti-
mate of liver injury in patients at risk. He/she agrees that
biopsy is not a perfect gold standard but still believes that
it is the best estimate. He admits that in caseswhere a biopsy
is contraindicated, validated biomarkers should be recom-
mended. He also admits that a biopsy is not recommended
for the screening of large populations. He rarely admits that
in case of discordance between a validated biomarker and a
25 mmbiopsy, the biopsy could be a false-positive or a false-
negative. He is typically the head of a Pathology unit.
(2) The ‘‘Biomarkerist’’ recommends validated biomarkers as
the ﬁrst-line estimate of liver injury in patients at risk.
He agrees that a biomarker is not a perfect test but believes
that it is as accurate as a 25 mm long liver biopsy for the
diagnosis of liver injury, with the same gray zones as liver
biopsy. In case of discordance between a biomarker and a
25 mm biopsy, he believes that the failure may be due to
either the biomarker or the biopsy (50%). He admits that
in order to be useful to clinicians, the biomarker of ﬁbrosis
must be available along with those of necrosis and steato-
sis. He admits that in case of non-interpretability of the
biomarker, another biomarker should be recommended,
and then if still not interpretable, a biopsy should be rec-
ommended as a third-line assessment. He is typically the
inventor of a biomarker, but not systematically a
‘‘BiomarkeTist’’.
(3) The ‘‘BioCocktailist’’ recommends a biomarker ﬁrst and
then a biopsy if the biomarker result is not convincing.
There are two subtypes in this proﬁle: the ‘‘Sequentialist’’
and the ‘‘Discordantist’’. The ‘‘Sequentialist’’ starts with
one biomarker and recommends biopsy if the result
belongs in what he calls a ‘‘gray zone’’. Curiously, he seems
to take the results of the biopsy in the gray zone as the
truth without risk of false positive/negative, even with
small length (<25 mm) biopsies. He does not like to discuss
the gray zones of biopsies between ﬁbrosis stages F1 and
F2. The ‘‘Discordantist’’ performs two biomarkers and rec-
ommends biopsy only in case of discordance. He ﬁnally11 vol. 54 j 586–587
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believes in the result supported by the concordance
between one of the biomarkers and biopsy. The BioCock-
tailist is typically a colleague of a ‘‘Biopsist’’ and a close
friend of a ‘‘Biomarkerist’’. The Discordantist usually also
has a statistician friend.Three main priorities
The ﬁrst urgent priority is to update the guidelines for the diag-
nosis of advanced ﬁbrosis as liver mortality increases worldwide.
Given the accumulation of data supporting non-invasive bio-
markers and their diagnostic value and risk/beneﬁt proﬁle, why
have we not already abandoned the 50-year old dogma of ﬁrst-
line investigation with biopsy?
In France (60 million inhabitants) the estimated number of
patients at risk of having liver diseases is around 12 million
(20%), including 1.8 million (3%) with advanced ﬁbrosis [9]. The
‘‘Biopsist’’ attitude for 50 years was a clear masquerade, with a
mean of only 10,000 biopsies per year, which signiﬁes that in
the most optimistic scenario only 0.6% (10,000/1.8 million) of
patients with advanced ﬁbrosis would have been identiﬁed. In
France biomarkers have been on the market since 2002, and
recent surveys have demonstrated that the prevalence of the
‘‘non-Biopsist’’ attitude now concerns 80% of specialists [4], with
an annual prescription of more than 60,000 FibroTests. This is 6
times more than for the biopsy but still too low as in the most
optimistic scenario, only 3.3% (60,000/1.8 million) of cases of
advanced ﬁbrosis are identiﬁed. We do believe, in accordance
with a pilot study in the general population, that a screening
strategy using biomarkers in subjects aged 40 years or older is
one way to signiﬁcantly reduce liver related mortality [9].
The second priority is to reassure the huge number (1.2 billion
worldwide) of subjects with steatosis (NAFLD or ALD) but with-
out advanced ﬁbrosis in terms of their prognosis. The validation
of simple and accurate biomarkers of steatosis coupled with bio-
markers of ﬁbrosis such as SteatoTest [10] should enable more
effective relationships to be built between general practitioners
and liver specialists [9].
The third priority is to improve the methodology. Many of
the (too) passionate discussions of biomarkers between leaders
are related to different levels of education in diagnostic statisti-
cal methods [11,12]. Two examples can be used to explain many
misunderstandings between leaders: (1) When there is no per-
fect gold standard, the classical estimates of accuracy (area
under the ROC curve, sensitivity, speciﬁcity, and predictive val-
ues) are false [11]; discordant analyses, latent class analysis
and prognostic analysis (using morbidity/mortality endpoints)
must be used [11–12]; (2) The accuracy of the diagnosis of
advanced ﬁbrosis or cirrhosis must be estimated by methods
that take into account the spectrum effect and the risk of multi-
ple testing [12,13].Journal of Hepatology 201Conclusion
Due to the dramatically insufﬁcient risk–beneﬁt ratio of biopsy
(40% coefﬁcient variation, 0.3% severe adverse events and 3/
10,000 mortality), it is surprising that many leaders and associa-
tions in the ﬁeld of hepatology still recommend it as the ﬁrst-line
investigation for millions of people exposed to the risk of ﬁbrosis.
Based on current evidence, a wise recommendation would be a
moratorium on liver biopsy as a ﬁrst-line procedure while await-
ing studies that demonstrate its cost-utility versus biomarkers.
Biopsy should not be abandoned however. Used as a third-line
estimate of liver injury, it should still be indicated for clinical–
biological discordances.Conﬂict of interest
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relationship with the manufacturers of the device/material
involved.
Inventor of FibroTest; capital interest in Biopredictive, the
company marketing the test. The patent belong to the Public
Organization Assistance Publique Hôpitaux de Paris.
References
[1] Poynard T. Uses of error. Lancet 2002;359:1514.
[2] Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, et al. A simple
biological index for detection of alcoholic liver disease in drinkers. Gastro-
enterology 1991;100:1397–1402.
[3] Halfon P, Munteanu M, Poynard T. FibroTest–ActiTest as a non-invasive
marker of liver ﬁbrosis. Gastroenterol Clin Biol 2008;32:22–38.
[4] Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving practices of non-
invasive markers of liver ﬁbrosis in patients with chronic hepatitis C in
France. Time for new guidelines? J Hepatol 2007;46:528–529.
[5] Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC. Guidelines for the
diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol
2007;31:504–509.
[6] Castera L, Pinzani M. Non-invasive assessment of liver ﬁbrosis: are we
ready? Lancet 2010;375:1419–1420.
[7] Afdhal NH. Diagnosing ﬁbrosis in hepatitis C: is the pendulum swinging from
biopsy to blood tests? Hepatology 2003;37:972–974.
[8] Ratziu V. Serum ﬁbrosis markers: death by validation or a leap of faith? J
Hepatol 2010;53:222–224.
[9] Poynard T, Lebray P, Ingiliz P, Varaud A, Varsat B, Ngo Y, et al. Prevalence of
liver ﬁbrosis and risk factors in a general population using non-invasive
biomarkers (FibroTest). BMC Gastroenterol 2010;10:40.
[10] Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The
diagnostic value of biomarkers (SteatoTest) for the prediction of liver
steatosis. Comp Hepatol 2005;4:10.
[11] Poynard T, Ingiliz P, Elkrief L, et al. Concordance in a world without a gold
standard: a new non-invasive methodology for improving accuracy of
ﬁbrosis markers. PlosOne 2008;3:e3857.
[12] Poynard T, Muntenau M, Morra R, et al. Methodological aspects for the
interpretation of liver ﬁbrosis non-invasive biomarkers: a 2008 update.
Gastroenterol Clin Biol 2008;32:8–21.
[13] Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, Carrat F. How to
measure the diagnostic accuracy of noninvasive liver ﬁbrosis indices: the
area under the ROC curve revisited. Clin Chem 2008;54:1372–1378.1 vol. 54 j 586–587 587
